使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, everyone, and welcome to today's DexCom's second quarter results conference all. Today's call is being recorded. (OPERATOR INSTRUCTIONS) I would now like to introduce your speakers for today. First we have Mr. Jeff Roper interim Chief Financial Officer, Mr. Steve Pacelli, Senior Vice President of Corporate Affairs, and Mr. Terry Gregg, Chief Executive Officer. At this time, I will turn the conference over to Mr. Steve Pacelli for opening remarks. Please go ahead, sir.
各位大家好,歡迎參加 DexCom 今日的第二季財報電話會議。今天的電話會議將被錄音。(OPERATOR INSTRUCTIONS)現在我想介紹今天的講者。首先是臨時財務長 Jeff Roper 先生、企業事務資深副總裁 Steve Pacelli 先生,以及執行長 Terry Gregg 先生。此刻我將把會議交給 Steve Pacelli 先生進行開場致詞。先生,請開始。
Steve Pacelli - SVP, Corporate Affairs
Steve Pacelli - SVP, Corporate Affairs
Thank you. I would just like to begin with a brief safe harbor statement. Statements we will make on this call may constitute forward-looking statements. These statements reflect management's expectations about future events, operating plans and performance and speak only as to the date hereof. These forward-looking statements involve a number of risks and uncertainties. Factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements are detailed under the risk factors and elsewhere in our annual report on Form 10 K, our quarterly report on 10 Q and other reports as filed in the FCC. We undertake no obligation to update publicly or revise forward-looking statements for any reason. I would now like to turn the call over to our President and Chief Executive Officer, Terry Gregg.
謝謝。我想先以一段簡短的「安全港」聲明作為開場。我們在本次電話會議中所做的陳述,可能構成前瞻性陳述。這些陳述反映管理層對未來事件、營運計畫與績效的預期,且僅截至本日有效。這些前瞻性陳述涉及多項風險與不確定性。可能導致實際結果與任何前瞻性陳述所明示或暗示者存在重大差異的因素,已在我們的 Form 10-K 年報、Form 10-Q 季報以及其他向 FCC 提交之報告中的風險因素與其他章節中詳述。我們不承擔因任何原因公開更新或修訂前瞻性陳述的義務。現在我想把電話會議交給我們的總裁兼執行長 Terry Gregg。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Thanks, Steve. I would like to set forth our agenda today. We are going to start off with a financial review of the second quarter with Jess Roper followed by a strategic review of the Company. I'd like to lead that off with really a a vision for the future. We will give you a bit of an update on the Seven launch. We will touch on reimbursement, go over our in hospital continuous glucose monitor, provide you with some additional information on the third generation sensor technology that we are developing, and summarize with some conclusions and then move into the Q&A. Jess?
謝謝你,Steve。我想先說明今天的議程。我們將先由 Jess Roper 進行第二季的財務回顧,接著進行公司的策略回顧。我想先以對未來的願景作為開場。我們會提供 Seven 上市的一些最新進展;也會談到給付(reimbursement);回顧我們的院內(in-hospital)連續血糖監測器;提供一些我們正在開發的第三代感測器技術的補充資訊;最後做出結論摘要,然後進入問答。Jess?
Jess Roper - Interim CFO
Jess Roper - Interim CFO
Thank you, Terry. DexCom Inc., the day before reported a net loss $11.3 million for the second quarter of 2007, or $0.40 per share, compared to a net loss of $11.2 million or $0.41 per share in the second quarter of 2006. We reported revenues of $863,000 for the second quarter of 2007, up 80% compared to revenue of $479,000 for the second quarter of 2006. We added 702 new customers during the second quarter and that number includes 77 seven day systems, After receiving approval of our Seven system, on May 31st we saw a delay in customers wanting to purchase our 3 day systems for a three week period until we launched our Seven system ADA. Customers preferred to wait for the Seven system. We decided not to aggressively address this customer hesitation prior to ADA as we strongly preferred to wait and start new customers on our Seven systems so they can realize its improved performance and features . We did announce an upgrade for our Link Q2 both for our existing three day customers and for those new three day customers who did not want to wait for the Seven launch to get started on the CGM . For $150, existing customers can upgrade to the Seven system. Any customer who purchased a three day system in June was offered a bundled upgrade. For those 167 customers with a bundled upgrade, we deferred $150 of revenue for each customer to allow their upgrade in Q3. This deferred revenue is approximately $25,000, and should be recognized in Q3 as we complete those upgrades.
謝謝你,Terry。DexCom Inc. 於前一日公布,2007 年第二季淨損為 1,130 萬美元(每股 0.40 美元),相較於 2006 年第二季淨損 1,120 萬美元(每股 0.41 美元)。我們 2007 年第二季營收為 863,000 美元,較 2006 年第二季的 479,000 美元成長 80%。第二季我們新增 702 位新客戶,其中包含 77 套七天系統。在我們於 5 月 31 日取得 Seven 系統核准後,我們觀察到客戶在三週期間內傾向延後購買我們的 3 天系統,直到我們在 ADA 推出 Seven 系統。客戶偏好等待 Seven 系統。我們決定在 ADA 之前不積極處理這種客戶猶豫,因為我們更希望讓新客戶直接從 Seven 系統開始使用,以便體驗其更佳的效能與功能。我們也在第二季宣布 Link 的升級方案,適用於既有的三天系統客戶,以及那些不想等 Seven 上市、希望先開始使用 CGM 的新三天系統客戶。既有客戶可支付 150 美元升級至 Seven 系統。任何在 6 月購買三天系統的客戶,皆可獲得綑綁式升級方案。對於這 167 位採用綑綁式升級的客戶,我們對每位客戶遞延 150 美元的營收,以便其於第三季完成升級。該遞延營收約為 25,000 美元,並應在第三季於我們完成這些升級時認列。
We continued to have good supplies of Seven inventories and continue to improve our manufacturing operations to allow more efficient scaling and to support the two product platforms as well as we upgrade programs. Hence, our revenues for the quarter were up over 280% compared to the second quarter of 2006. Our gross margin loss of $2 million for the second quarter of 2007 increased $431,000 compared to a loss of $1.6 million during the second quarter of 2006. However the second quarter of 2006 loss was lowered by $1.1 million due to a credit. In that period the materials purchased and expensed for 2005, were still developed by the [stage] organization. Without the impact of the 2006 credit, the gross margin will have improved over $500,000 in 2007 to 2006. The improvement was due to our higher revenues as well as lower direct labor spending. We're very pleased to see the continued improvement in our manufacturing capabilities and yields which translated into better gross margin performance.
我們持續維持充足的 Seven 庫存供應,並持續改善製造營運,以提升擴產效率,並支援兩個產品平台以及我們的升級計畫。因此,本季營收較 2006 年第二季成長超過 280%。2007 年第二季毛利損失為 200 萬美元,較 2006 年第二季的 160 萬美元損失增加 431,000 美元。然而,2006 年第二季的損失因一筆 110 萬美元的貸項而降低。在該期間,於 2005 年採購並費用化的材料,仍由 [stage] 組織進行開發。若不考慮 2006 年該筆貸項的影響,2007 年相較 2006 年的毛利將改善超過 500,000 美元。改善主要來自較高的營收以及較低的直接人工支出。我們很高興看到製造能力與良率持續提升,並轉化為更佳的毛利表現。
Research and development decreased $1.3 million to $4.0 million for the second quarter of 2007 compared to $5.4 million for the second quarter of 2006. Changes in R&D expense included $500,000 in lowered clinical and regulatory costs, and $1 million in lower development expenses, partially offset by higher quality assurance costs. The major elements of the decline in Research &Development costs include $467,000 in clinical trial expenses , $262,000 in lower tooling and fixturing costs and $163,000 in lower facilities costs. Our clinical trial expenses were higher in the second quarter of 2006 as we were in completing a civil trial for a seven day sensor submitted on behalf of the FDA. Although the clinical costs were lower this quarter we expect those costs to return to previous levels as we move to new products and indications through the regulatory cycle. The tooling and fixturing costs were relatively high in the 2006 quarter as we were completing the scaling up of a three-day product launch. Those expenses have moderated as our manufacturing operations mature. R&D expense was flat sequentially with Q1 2007.
2007 年第二季研發費用較 2006 年第二季的 540 萬美元減少 130 萬美元至 400 萬美元。研發費用的變動包括:臨床與法規成本降低 500,000 美元,以及開發費用降低 100 萬美元,但部分被較高的品質保證成本所抵銷。研發成本下降的主要項目包括:臨床試驗費用減少 467,000 美元、模具與治具成本降低 262,000 美元,以及設施成本降低 163,000 美元。2006 年第二季臨床試驗費用較高,因為我們當時正完成一項為 FDA 提交之七天感測器的民用試驗。雖然本季臨床成本較低,但隨著我們推進新產品與新適應症並進入法規循環,我們預期這些成本將回到先前水準。2006 年該季的模具與治具成本相對較高,因為我們當時正完成三天產品上市的擴產作業。隨著製造營運成熟,這些費用已趨於緩和。研發費用與 2007 年第一季相比呈現持平。
SG&A expenses increased $537,000 to $5.5 million for the second quarter of 2007 compared to $4.9 million for the second quarter of 2006. The increase was primarily due to $419,000 in higher general &administrative expenses and $118,000 higher sales and marketing expense. Major elements in the increased expense include $853,000 in higher compensation expense, and $154,000 in higher consulting costs primarily due to $400,000 in separation payments to our former CEO which was partially by $129,000 in lowered legal expense. Stock based compensation costs declined $50,000 to $862,000 in the second quarter of 2007 compared to $912,000 for the same quarter in 2006. The $269,000 in one-time expense related to the CEO separation cost for extended option vesting extended exercise period was more than offset by the decline in value in vesting grants overall. Operating loss of $11.5 million improved $364,000 compared to our operating loss of $11.9 million for the second quarter of 2006. This slightly higher gross margin loss was more than offset by $795,000 in lowered operating expenses. Net interest income interest expense decreased $532,000 to $204,000 for the second quarter of 2007 compared to $736,000 for the second quarter of 2006. The decrease was due to a $914 000 increase in interest expense primarily related to our $60 million of convertible loan, partially offset by $382,000 higher interest income.
2007 年第二季銷售、一般及行政(SG&A)費用較 2006 年第二季的 490 萬美元增加 537,000 美元至 550 萬美元。增加主要來自一般及行政費用增加 419,000 美元,以及銷售與行銷費用增加 118,000 美元。費用增加的主要項目包括:薪酬費用增加 853,000 美元,以及顧問費用增加 154,000 美元;其中顧問費用主要與支付給前任 CEO 的 400,000 美元離職補償金有關,並部分被法律費用降低 129,000 美元所抵銷。以股票為基礎的薪酬成本在 2007 年第二季下降 50,000 美元至 862,000 美元,低於 2006 年同季的 912,000 美元。與 CEO 離職相關的一次性費用 269,000 美元(涉及選擇權歸屬延長與延長行使期間)已被整體歸屬授予價值下降所抵銷。營業損失為 1,150 萬美元,較 2006 年第二季的 1,190 萬美元營業損失改善 364,000 美元。略高的毛利損失已被營業費用降低 795,000 美元所抵銷。淨利息收入/利息費用在 2007 年第二季由 736,000 美元下降 532,000 美元至 204,000 美元。下降原因為利息費用增加 914,000 美元,主要與我們 6,000 萬美元可轉換貸款相關,部分被利息收入增加 382,000 美元所抵銷。
We ended the quarter with a strong balance sheet. As of June 30, 2007, we had $84.2 million cash equivalents and working capital of $80.1 million. We continue to focus on controlling our expense and cash burn continue to be pleased with our progress during the second quarter. Net cash used in operating activities decreased $9.2 million to $15.8 million in six months ending June 30th, 2007, compared to $25.0 million net cash for the same period in 2006. The decrease in cash usage operations is primarily due to $3.2 million less cash to invest in inventories, $3.7 million less cash used to pay down payable and accrue liabilities compared to the same period in 2006. During the quarter we invested $391,000 in capital equipment and facilities to support our business. As a result of non-cash expenses including $1.6 million of stock based compensation, $645,000 in depreciation and liability changes, our cash usage from operations of $8.3 million in the quarter was much less than the reported net loss of $11.3 million. We continue to build our business in a cash efficient manner. I will now, turn it back over to the CEO, Terry Gregg.
本季結束時,我們的資產負債表相當穩健。截至 2007 年 6 月 30 日,我們持有 8,420 萬美元的現金及約當現金,營運資金為 8,010 萬美元。我們持續專注於控制費用與現金消耗,並對第二季的進展感到滿意。截至 2007 年 6 月 30 日止六個月,營運活動使用的淨現金較 2006 年同期的 2,500 萬美元減少 920 萬美元至 1,580 萬美元。營運現金使用量下降主要因為:投入存貨的現金減少 320 萬美元,以及用於償付應付帳款與應計負債的現金較 2006 年同期減少 370 萬美元。本季我們投資 391,000 美元於資本設備與設施以支援業務。由於包含 160 萬美元股票基礎薪酬、645,000 美元折舊及負債變動等非現金費用,使得本季營運現金使用 830 萬美元,遠低於報告的 1,130 萬美元淨損。我們將持續以高現金效率的方式拓展業務。現在我把電話會議交回給執行長 Terry Gregg。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Thanks, Jess. Although I have only been at DexCom for approximately five weeks I have been involved in the diabetes space for more than a decade. During that time I have had the opportunity to participate in and lead the adoption of novel technologies that significantly improve the clinical outcomes of patients with diabetes. I am fortune to once again be given that leadership role in the further development and adoption of a new technology that is able to address a very large diabetes population. The clinical consequences of diabetes hinge on the inability to maintain normal glucose levels. Insulin is a tool but not a cure. Other injectables and oral agents may help to reduce the extreme excursions in glucose levels but the real key to reducing the unforeseen clinical events of diabetes is understanding the glycemic profile of patients. This can only be accomplished by continuous glucose measurements, and if glucose is the culprit then knowing the total glucose exposure, a patient experiences each day is extremely an important in controlling these excursions.
謝謝你,Jess。雖然我在 DexCom 任職大約只有五週,但我在糖尿病領域已投入超過十年。在那段期間,我有機會參與並領導新穎技術的導入,這些技術能顯著改善糖尿病患者的臨床結果。我很幸運能再次被賦予領導角色,推動一項可涵蓋非常龐大糖尿病族群之新技術的進一步開發與採用。糖尿病的臨床後果取決於無法維持正常血糖水準。胰島素是一種工具,但不是治癒方法。其他注射劑與口服藥物或許能協助降低血糖水準的劇烈波動,但降低糖尿病不可預期臨床事件的真正關鍵,在於了解患者的血糖曲線。這只能透過連續血糖量測來達成;而若血糖是罪魁禍首,那麼掌握患者每日所承受的總血糖暴露量,對於控制這些波動極其重要。
With our leadership role in the category, we will continue to invest in activities, to grow the category by increasing acceptance of CGM as the best standard of care for diabetes management. While our second generation continuous glucose monitoring system, the Seven, is approved for adults, we are actively engaged in an effort to secure a pediatric indication and we are currently conducting feasibility trials within that population. As we said previously, we believe that there are performance differences between pediatric and adult patients and we intend to commercialize a product optimized for the pediatric population. I believe that many of the improvements I will outline in our discussion on our third generation product will be applicable to a product optimized for this key target population.
憑藉我們在此類別中的領導地位,我們將持續投資各項活動,透過提升對 CGM 作為糖尿病管理最佳照護標準的接受度來擴大此類別。雖然我們第二代連續血糖監測系統 Seven 已獲核准用於成人,我們正積極投入爭取兒科適應症,並且目前正在該族群中進行可行性試驗。如同我們先前所述,我們相信兒科與成人患者之間存在效能差異,我們也打算將一款針對兒科族群最佳化的產品商業化。我相信,在我們討論第三代產品時我將概述的許多改良,也將適用於針對這個關鍵目標族群最佳化的產品。
Diabetes is a global disease and I believe DexCom should be participating in key international markets particularly the European Union countries. We have begun pursuing a CEO (inaudible) for the Seven and expect to provide an update regarding timing on our next quarterly call. Additionally, we have been asked by several European diabetes thought leaders to begin discussions about introducing the Seven in Europe in 2008. To that end we will be attending European Association's for the Study of Diabetes annual meeting in Amsterdam later this year to begin that effort.
糖尿病是一種全球性疾病,我認為 DexCom 應參與關鍵的國際市場,特別是歐盟國家。我們已開始為 Seven 申請 CE(聽不清),並預期在下一次季度電話會議中提供時程更新。此外,已有數位歐洲糖尿病意見領袖要求我們開始討論於 2008 年在歐洲導入 Seven。為此,我們將於今年稍晚出席在阿姆斯特丹舉行的歐洲糖尿病研究協會(EASD)年會,以啟動這項工作。
I have been asked recently about pending partnerships, particularly with the pump company. We're very receptive to having discussions with potential partners and believe an open architecture whereby our sensor system is adaptable to multiple pump models representing the best interests of the patients and DexCom. Since the pump represents a relatively small percentage of the insulin using population, we believe it would be foolish to align the Company with a single pump manufacturer. I recognize patients utilizing continuous insulin infusion systems are traditionally considered early adopters of technology. However, any patient on a pump today can in fact use the DexCom CGM system to aid them in managing their diabetes.
最近有人問我關於尚在洽談中的合作夥伴關係,特別是與幫浦公司之合作。我們非常樂於與潛在合作夥伴進行討論,並相信採用開放式架構,使我們的感測器系統可適配多種幫浦機型,最符合患者與 DexCom 的最佳利益。由於幫浦僅占使用胰島素族群中相對較小的比例,我們認為若讓公司與單一幫浦製造商結盟將是愚蠢之舉。我理解使用連續胰島素輸注系統的患者傳統上被視為科技的早期採用者。然而,事實上,任何目前使用幫浦的患者都可以使用 DexCom CGM 系統來協助其管理糖尿病。
The discussion surrounding integrated and automated pump sensor systems, creating what is currently termed an artificial pancreas, is extremely premature. As you well know, diabetes is a multifactorial disease that requires more sophistication than pumps, sensors and algorithms to effectively mimic the metabolic and physiological reactions for rising or falling glucose levels. There are numerous internal and external factors that hardware and software simply cannot duplicate. As we previously announced, on May 31st, we received approval from the FDA to begin commercially marketing our second generation continuous monitoring system, the DexCom Seven. The Seven is the first continuous glucose monitor to be approved up to seven days of continued use of a single sensor. It is indicated for use by adults over 18 with type I and type II diabetes at home or in health care facilities as a complement to a standard home glucose monitoring device. The indication statement clearly states that the Seven aids in the detection of episodes of hyperglycemia and hypoglycemia facilitating acute and long-term therapeutic adjustments which may minimize these excursions. We're very pleased with the continued emphasis on the therapeutic aim and labeling of the device. We believe the Seven is a better performing second generation product with both true performance benefits and more ease of use and convenience. As we ramp up the launch of the Seven the next several months, we anticipate it will create more positive initial experiences for patients and health care professionals which we believe is critical to building this emerging category.
圍繞整合式與自動化幫浦—感測器系統(目前稱為人工胰臟)的討論,仍然極為不成熟。正如各位所知,糖尿病是多因素疾病,要有效模擬血糖上升或下降時的代謝與生理反應,所需的精密程度遠超過幫浦、感測器與演算法所能達成。存在許多內外在因素,是硬體與軟體根本無法複製的。如同我們先前宣布的,5 月 31 日我們已獲 FDA 核准,開始商業化行銷我們第二代連續監測系統 DexCom Seven。Seven 是第一款獲核准可使用單一感測器連續使用長達七天的連續血糖監測器。其適應症為 18 歲以上第一型與第二型糖尿病成人,可於家中或醫療照護機構使用,作為標準居家血糖監測裝置之輔助。適應症敘述清楚指出,Seven 有助於偵測高血糖與低血糖發作,促進急性與長期治療調整,從而可能將這些波動降至最低。我們對於標示與裝置持續強調治療目標感到非常滿意。我們相信 Seven 是一款表現更佳的第二代產品,兼具真正的效能優勢以及更高的易用性與便利性。隨著我們在未來幾個月加速推進 Seven 的上市,我們預期它將為患者與醫療專業人員帶來更正面的初期體驗,而我們相信這對於建立這個新興類別至關重要。
As we move into the third quarter our focus will be on the 40 to 50 largest diabetes centers in the U.S. We are now, providing initial launch inventory for these accounts. We will continue to move methodically through the rollout process with the Seven and to make use of all rampup lessons we learned with the FTS three day launch. We believe the improvements we have made in our manufacturing operations with the three day are transferable to the Seven. Our initial focus will be on new patients although we hope to rapidly move to upgrading those loyal current users with the desire to move up to the Seven.
進入第三季後,我們的重點將放在美國規模最大的 40 到 50 家糖尿病中心。我們目前正為這些客戶提供首批上市庫存。我們將持續以有條不紊的方式推進 Seven 的鋪貨流程,並運用我們在 FTS 三日上市過程中所學到的所有擴產經驗。我們相信,我們在三日產品製造作業上所做的改進可移轉至 Seven。我們初期將聚焦於新患者,儘管我們希望能迅速推進,為那些忠誠的既有使用者升級,滿足其升級至 Seven 的需求。
Patients who purchased the Seven received a new version of our PC software. Our new software has more extensive analytical and statistical tools to allow patients and their doctors to more fully fully analyze and interpret glucose data to guide them through the most appropriate use of CGM to improve glucose control. Additionally during the second quarter we filed a PMA supplement with the FDA to add additional functionality to the Seven to enable patients to calibrate the system using any brand of blood glucose meter. We expect the Seven will generate new excitement and interest in the CGM category. The Seven provides us a chance to meaningfully revisit the benefit of continuous glucose monitoring with both patients and health care professionals who might have been resistant to any first generation product, who might have been an unfavorable initial experience with CGM, or who might have wondered if DexCom would only be one product company. With the Seven we continue to provide leadership to the category in bringing a second-generation product forward.
購買 Seven 的患者會收到我們 PC 軟體的新版本。我們的新軟體具備更完整的分析與統計工具,使患者及其醫師能更全面地分析與解讀血糖資料,並引導其以最適當的方式使用 CGM 以改善血糖控制。此外,在第二季我們向 FDA 提交了 PMA 補充申請,為 Seven 增加額外功能,使患者可使用任何品牌的血糖機來校正系統。我們預期 Seven 將在 CGM 類別中帶來新的興奮與關注。Seven 也讓我們有機會與患者及醫療專業人員有意義地重新檢視連續血糖監測的效益——包括那些可能對任何第一代產品有所抗拒者、可能曾有不佳的 CGM 初期體驗者,或可能曾懷疑 DexCom 是否只是一家單一產品公司的人。透過 Seven,我們持續在推動第二代產品上市方面為此類別提供領導力。
Product performance and quality as measured by complaint rate data continues to be positive while at the same time manufacturing volumes have increased as we ramp up the launch of the Seven. Qualitative reports from our field personnel about product performance are also encouraging and we expect this to continue as we roll out the Seven. One of our single source suppliers of materials used in our membrane system has recently experienced difficulties in providing us with the materials which consistently meet our specifications. We're working closely with the supplier to resolve these issues. Additionally, we are taking steps to bring on a second source supplier of these materials.
以客訴率資料衡量的產品效能與品質持續呈現正向表現,同時,隨著我們加速推進 Seven 的上市,製造量也已增加。我們前線人員對產品效能的質性回饋同樣令人鼓舞,我們預期在推廣 Seven 的過程中這種情況將持續。我們膜系統所用材料的其中一家單一來源供應商,近期在提供能持續符合我們規格的材料方面遇到困難。我們正與該供應商密切合作以解決這些問題。此外,我們也正採取措施,導入該等材料的第二來源供應商。
We continue to receive unsolicited reports from patients and physicians of favorable coverage decisions and our own reimbursement organization is working to most appropriately build upon these experiences to create wider reimbursement especially with private payers. We continue to believe the private payers are a very important constituency in diabetes. Novel technology introductions and adoptions is always a reimbursement challenge. We are fortunate to have certain standards established for glucose level goals as outlined by the DCCT and ADA standards of care. The payer community is well versed in the health/economic benefits of better glycemic control in the diabetes population. Our goal is to establish the role of CGM in assisting patients to better manage their glucose excursions, both hypoglycemia and hyperglycemia.
我們持續收到來自患者與醫師的非主動回報,指出有利的給付(承保)決策;同時,我們自身的報銷/給付團隊正努力在這些經驗之上,以最適當的方式擴大推進,尤其是針對民間保險支付方,以建立更廣泛的給付。我們仍然相信民間支付方是糖尿病領域非常重要的利害關係人。新技術的導入與採用一向面臨給付挑戰。我們很幸運已有由 DCCT 與 ADA 照護標準所界定的血糖目標等既定標準。支付方社群對於在糖尿病族群中改善血糖控制所帶來的健康/經濟效益相當熟悉。我們的目標是確立 CGM 在協助患者更好管理血糖波動(低血糖與高血糖)方面的角色。
At the present time more at risk patients of the logical recipients of coverage. However, it is clear there are a number of patients who simply cannot achieve acceptable glucose levels without the continuous glucose management system. The reimbursement process takes time, patience and perseverance. The JDRS-sponsored randomized reimbursement trial is continuing to enroll. The design of the trial is very comprehensive and should provide a wide and thorough array of data the payers will find useful for coverage decisions. Our own outcome study which demonstrated statistically significant improvement in (inaudible) C levels in 140 patients using the DexCom CGM system was peer reviewed/published in the June issue of Diabetes Technology and Therapeutics. When combined with our two previous publications demonstrating improved outcomes, this outcome data should allow us to more aggressively approach payers. We are making progress but I cannot predict when broad coverage will be generally available.
目前而言,風險較高的患者是較合乎邏輯的給付對象。然而,很明顯有相當一部分患者若沒有連續血糖管理系統,就無法達到可接受的血糖水準。給付流程需要時間、耐心與毅力。由 JDRS 贊助的隨機給付試驗仍在持續收案。該試驗設計非常全面,應能提供廣泛且完整的資料,讓支付方在做出給付決策時認為有用。我們自身的結果研究顯示,140 名使用 DexCom CGM 系統的患者其(聽不清)C 水準有統計上顯著改善,該研究已通過同儕審查並發表於《Diabetes Technology and Therapeutics》六月號。結合我們先前兩篇顯示改善結果的發表,這些結果資料應能讓我們更積極地接觸支付方。我們正在取得進展,但我無法預測何時能普遍取得廣泛給付。
We continue to believe that the in-hospital application of CGM is a very important and large market opportunity especially in a critical care arena. Published data continues to provide compelling evidence that intensive glucose control and insulin therapy and post surgery intensive care units significantly reduces mortality and morbidity. Intensive glucose control and insulin regimen therapies are continuing to be addressed and evaluated by accreditation bodies. Without specifically trying to quantify the market at this time, there are an estimated 100,000 critical beds in the U.S., and 25% of U.S. hospitals have implemented in intensive glucose control and insulin therapy often involving 12 to 24 bedside finger stick tests per day. There are also estimates that 25% of patients admitted to the hospital have diabetes. There are approximately 450,000 cardiovascular surgeries per year and approximately 30% of these patients have diabetes.
我們仍然相信,CGM 在院內的應用是一個非常重要且龐大的市場機會,尤其是在重症照護領域。已發表的數據持續提供有力證據顯示,在術後加護病房中,嚴格的血糖控制與胰島素治療可顯著降低死亡率與罹病率。嚴格血糖控制與胰島素治療方案仍持續受到認證機構的關注與評估。目前不特別嘗試量化市場規模,但美國估計約有 100,000 張重症病床,且美國約 25% 的醫院已實施嚴格血糖控制與胰島素治療,通常每天需要進行 12 至 24 次床邊指尖採血測試。另有估計指出,住院病患中約有 25% 罹患糖尿病。每年約有 450,000 例心血管手術,其中約 30% 的患者患有糖尿病。
For those hospitals practicing intensive glucose control, CGM could significantly reduce the workload and costs while improving the quality of care. Studies have estimated the costs of these bedside finger stick tests at $3 to $5 per test. We continue to conduct human feasibility trials with our in-hospital system and are continuing to refine the product. We're very pleased with the speed and progress of the project and we are working to rapidly evolve the technology into a commercial product platform. In early July we had a productive meeting with the FDA to determine the most appropriate regulatory pathway for product approval. Although it is still too early to predict commercialization timeline, we are working to define the best clinical and regulatory path for the product.
對於實施嚴格血糖控制的醫院而言,CGM 可在提升照護品質的同時,顯著降低工作量與成本。研究估計,這些床邊指尖採血測試的成本為每次 3 至 5 美元。我們持續以院內系統進行人體可行性試驗,並持續精進產品。我們對該專案的速度與進展感到非常滿意,並正努力將此技術快速演進為商業化產品平台。7 月初我們與 FDA 進行了一次富有成效的會議,以確定最適當的產品核准監管途徑。雖然目前仍太早預測商業化時程,但我們正致力於界定該產品最佳的臨床與監管路徑。
Moving to our generation III products, we believe the continual introduction of next-generation products with improved performance are key to the development and the growth of the CGM category. We are currently in the final development stages for our third generation short-term continuous glucose monitoring system and we expect to complete a pivotal trial for this next generation product early in the fourth quarter and file a PMA supplement with the FDA shortly thereafter. We have incorporated many improvements into the device to enhance usability and configurability including a 75% reduction in implanted sensor sides. This is especially important considering DexCom already has the smallest sensor available in the marketplace. It will further reduce the needle size down to a 28 gauge from the current 26 gauge.
談到我們的第三代產品,我們相信,持續推出具備更佳效能的次世代產品,是 CGM 類別發展與成長的關鍵。我們目前正處於第三代短期連續血糖監測系統的最終開發階段,預期將於第四季初完成此下一代產品的關鍵性試驗,並在其後不久向 FDA 提交 PMA 補充申請。我們在裝置中納入多項改良,以提升易用性與可配置性,包括植入式感測器尺寸縮小 75%。這點尤其重要,因為 DexCom 已擁有市場上最小的感測器。這也將把針頭尺寸從目前的 26 號進一步縮小至 28 號。
We will add the addition of trend barrels to complement our trend graph, more customization including unique tones for high/low glucose levels, vibrate only capabilities, alert/snooze. We will add event entry capabilities such as insulin intake, meals and exercise and that will also include the addition of a 12 and/or 24 hour screen. We anticipate that our next generation system will make the device even more user-friendly and intuitive to allow patients to be trained more efficiently and begin using the system more rapidly and with less follow-up on support from DexCom or the prescribing sites required.
我們將新增趨勢柱(trend barrels)以補強我們的趨勢圖,並提供更多客製化功能,包括高/低血糖的獨特提示音、僅震動功能、警示/延後提醒。我們也將新增事件輸入功能,例如胰島素注射、用餐與運動,並將加入 12 小時及/或 24 小時畫面。我們預期下一代系統將使裝置更易用、更直覺,讓病患能更有效率地接受訓練、更快速開始使用,且所需的 DexCom 或開立處方之醫療機構後續支援更少。
In summary, as we launch the Seven we believe as much as ever that CGM will increasingly play an important role in the diabetes management and will be a growing and profitable business in the future. DexCom has emerged as a clinical technology and market leader in CGM. We are determined to ensure DexCom has the presence and staying power to help drive development in the CGM market and to meaningfully participate as it evolves. We remain committed to our three-pronged strategy.
總結而言,隨著我們推出 Seven,我們比以往更相信 CGM 將在糖尿病管理中扮演日益重要的角色,並在未來成為一項成長且具獲利性的業務。DexCom 已成為 CGM 的臨床技術與市場領導者。我們決心確保 DexCom 具備市場能見度與持久力,以協助推動 CGM 市場的發展,並在其演進過程中有實質參與。我們仍致力於我們的三管齊下策略。
First, continued developing next-generation products for the performance that appeals to larger segments of the target population including potential partnership that provide for the integration of diabetes management technologies. Second, create the data, experiences and the evidence for health care professionals to widely accept t and adopt CGM as the primary means for diabetes management. We believe the approval and launch of the DexCom Seven demonstrates our ability to stay focused and rapidly introduce products with new product improvement and product enhancement. We expect to continue moving our third generation short-term continuous monitoring product and our in hospital products rapidly towards commercialization. Thank you.
第一,持續開發次世代產品,以提供能吸引目標族群更大區隔的效能,包括可能的合作夥伴關係,以整合糖尿病管理技術。第二,建立數據、經驗與證據,使醫療專業人員能廣泛接受並採用 CGM 作為糖尿病管理的主要方式。我們相信 DexCom Seven 的核准與上市,展現了我們能保持專注並快速推出具新產品改良與強化的產品。我們預期將持續快速推進第三代短期連續監測產品與院內產品的商業化。謝謝。
Operator
Operator
(OPERATOR INSTRUCTIONS) We're going to take our first question from Tom Gunderson of Piper Jaffray.
(接線員指示)我們將先接聽 Piper Jaffray 的 Tom Gunderson 的第一個問題。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
All right. Good afternoon. Just a couple to clarify, with 702 new customers in the quarter if I heard correctly, but revenues were flat and I believe that was due to --if you could just say it one more time in a different way -- a three week hiatus where people were waiting to maybe go to the seven day and were holding back on the three day reorders? Is that right?
好的。下午好。只是幾點釐清一下,如果我沒聽錯,本季新增 702 位新客戶,但營收持平,我相信那是因為——如果你能用不同方式再說一次——有三週的空窗期,因為大家可能在等七天款,所以暫緩了三天款的補貨再訂購?是這樣嗎?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Tom, this is Terry.That is right. We saw that there was some holdout from the three day moving. If you remember we really introduced it at the ADA in Chicago in mid June. So there were people were waiting until after the initial launch.
Tom,我是 Terry。沒錯。我們確實看到有些人暫緩從三天款轉換。如果你還記得,我們是在 6 月中於芝加哥的 ADA 才正式推出。所以有些人一直等到初期上市之後。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
And as far as any back order or turnaround time issues Terry, now, with this seven day or the three day?
另外 Terry,就七天款或三天款而言,目前有任何缺貨或交期周轉時間的問題嗎?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
No. We are not in any back order situation.
沒有。我們目前沒有任何缺貨情況。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
And you said you wanted to go to the top 40 to 50 diabetes center with the seven day. Where are you with those on the three day right now?
你提到七天款想先鎖定前 40 到 50 家糖尿病中心。那三天款目前在那些中心的進展如何?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
I think the original approach was to get the information out with regards to the benefit of CGM to a large population. I think at this point we have -- I would say we have refocused the sales force to go back in and identify those key thought leaders at very large practices, and certainly we are participating with the three day in some of those centers, as well. But I think we have been scattered at times and we are definitively focused and have identified those centers and have been calling on them for the last four to five weeks.
我認為最初的做法是把 CGM 的效益資訊傳達給更廣大的族群。我想目前我們——我會說我們已重新聚焦銷售團隊,回到現場去辨識那些在大型診所中的關鍵意見領袖;當然,我們也在其中一些中心推動三天款。不過我認為我們有時候分散了焦點,而現在我們已明確聚焦、也已辨識出那些中心,並在過去四到五週持續拜訪。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay, and the last question and I will let others ask is you talked about the importance of a pediatric indication. I know the JDRS study is using the seven day. Is your studies now going forward to gather data for the FDA for pediatric indications on the seven day or on the third generation or anything else?
好的,最後一個問題我就讓其他人提問。你談到兒科適應症的重要性。我知道 JDRS 研究使用的是七天款。你們目前進行中的研究,是要為 FDA 蒐集七天款的兒科適應症資料,還是第三代或其他產品?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
At the present time we are engaged in the pediatric population with the seventh day. That said, as you look at the benefits of a third generation, we believe that given some of the challenges of that pediatric population, with rapid glucose changes due to a variety of hormonal changes and other challenges that they experience, we can better accommodate that with the third generation.
目前我們在兒科族群方面是以七天款在進行。不過,從第三代的效益來看,我們相信,考量兒科族群的一些挑戰——例如因各種荷爾蒙變化造成的血糖快速波動,以及他們所面臨的其他挑戰——我們可以用第三代更好地因應。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay. Thanks Terry.
好的。謝謝 Terry。
Operator
Operator
We're going to take our next question from Mimi Pham of HSBC.
我們將接聽下一個問題,來自 HSBC 的 Mimi Pham。
Mimi Pham - Analyst
Mimi Pham - Analyst
Hi. Good evening. Could you remind us of your current central manufacturing capacity and do you have goals in terms of improving that for exiting '07 and into '08?
嗨,晚安。你能提醒我們目前中央製造產能是多少嗎?以及你們是否有目標在 2007 年底到 2008 年期間提升產能?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Mimi, this is Terry. We haven't disclosed that previously and I would not want to do that at this time.
Mimi,我是 Terry。我們之前沒有揭露過那個數字,而我目前也不希望在此時揭露。
Mimi Pham - Analyst
Mimi Pham - Analyst
Given the delay in the Abbott navigator device, are you sensing the doctors and patients that they are waiting for that to come out before ordering the seventh day? Is that impacting orders for our people -- That is not really coming into play?
鑑於 Abbott Navigator 裝置延遲,你是否感受到醫師與病患在等它上市後才訂購七天款?這是否正在影響我們的訂單——還是其實沒有太大影響?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
I can't really comment on what patients are doing relative to a competitor. I can only comment that the results we are experiencing from the field and listening to patients on their call-in and their letters and testimonials that they are very satisfied with the Seven. And I wouldn't want to comment any more than that.
我無法就病患相對於競品的行為做評論。我只能說,就我們從前線得到的回饋,以及聽取病患來電、信件與見證的結果,他們對 Seven 非常滿意。我不想再多做評論。
Mimi Pham - Analyst
Mimi Pham - Analyst
Thanks and the last question, do you have a sense of the attrition rate for the patients on the three day STS?
謝謝,最後一個問題,你們是否掌握三天 STS 病患的流失率?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
We are still trying to capture that information in order to provide us with feedback to go back and understand if there is particular reasons for the attrition but it is not something that I can dial in at this point. I have asked to capture that information but right now, that is not available to us.
我們仍在嘗試蒐集該資訊,以便提供回饋,讓我們回頭了解是否有特定的流失原因,但目前我還無法精確掌握。我已要求蒐集這些資訊,但現在我們還沒有可用的資料。
Mimi Pham - Analyst
Mimi Pham - Analyst
Thank you.
謝謝你。
Operator
Operator
We'll take our next question from Bill Plovanic of Canaccord Adams.
我們將接聽下一個問題,來自 Canaccord Adams 的 Bill Plovanic。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Great. Thank you, can you hear me okay?
太好了,謝謝。你聽得到我說話嗎?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Yes, Bill.
聽得到,Bill。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Fantastic. Just a couple of questions here. In terms of the pediatrics product, is the gen three the pediatric product or are they two separate products?
太棒了。我這裡有幾個問題。就兒科產品而言,第三代就是兒科產品嗎?還是它們是兩個不同的產品?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Well, clearly the Seven which has been in clinical trials with the pediatric population is a product and the third generation is yet another product. So, I think we are talking about two different products. As I indicated in my comments I believe that the next generation, what we call the third generation product has attributes associated with that will more readily adopted itself and optimize to the pediatric population.
嗯,很明顯地,已在兒科族群進行臨床試驗的 Seven 是一項產品,而第三代又是另一項產品。所以,我認為我們談的是兩個不同的產品。正如我在評論中所指出的,我相信下一代、也就是我們所稱的第三代產品,具備一些特性,將更容易被採用,並更能針對兒科族群進行最佳化。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Okay, so they both address the pediatric population?
好的,所以它們兩者都針對兒科族群?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
That is correct.
沒錯。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Okay. Thanks for the clarification. You mentioned 75% decrease in sensor size for gen three, is that in the transmitter that you're talking about?
好的。謝謝澄清。你提到第三代感測器尺寸縮小 75%,你指的是發射器嗎?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
No. We are talking about the sensor.
不是。我們指的是感測器。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
The actual sensor?
實際的感測器?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Correct.
對。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Okay. And then in terms of the calibration, I take it will be a manual calibration as you go forward? That's the DMAS that you filed?
好的。那在校準方面,我理解未來會是手動校準?也就是你們提交的 DMAS?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
That is correct. Yes.
沒錯。是的。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Okay. Lastly, you mentioned that probably the target population at least in the near term in terms of gaining reimbursement is going after that high-risk population for hypo and hyperglycemic. If you had to nail it down in terms of the type Is using and the type IIs that are effectively type Is at this point, what percentage of those populations would you think were at risk or the target that you're speaking of?
好的。最後,你提到就爭取給付而言,至少在短期內的目標族群,可能是針對低血糖與高血糖的高風險族群。如果要更具體一點,以第 1 型使用者以及那些實際上目前等同於第 1 型的第 2 型來看,你認為這些族群中有多少比例屬於你所說的風險族群或目標族群?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Well, I mean, from my now 13, 14 years of experience in diabetes, I would say 100%. I mean, these patients have hyperglycemic excursions on a daily basis. That has been demonstrated by a number of studies. Does that translate into extreme at risk patients, I don't think we entirely know the answer to that yet. That was part of my earlier comment in regards to the total glycemic excursion and the total glycemic exposure.
嗯,以我在糖尿病領域 13、14 年的經驗來看,我會說是 100%。我的意思是,這些病患每天都會出現高血糖波動。許多研究已經證明了這點。這是否就等同於「極高風險」病患?我認為我們還不完全知道答案。這也呼應我先前提到的總血糖波動與總血糖暴露。
Until we get a better understanding of what that means to patients without diabetes who don't suffer the long-term clinical consequences, it is an evolving knowledge base that we don't have a good handle on. Clearly, those who have demonstrated, ER visits is a good example, it is fairly easy to know that they are at a higher risk because of their clinical consequences on an acute basis. We know that on the hyper side, the long-term challenges to the cardiovascular system alone, as a result -- excessive glucose exposure can be devastating. I am not trying to evade the question, I just don't think anybody has the statistics we're looking for right now.
在我們更了解這對沒有糖尿病、且不會承受長期臨床後果的病患意味著什麼之前,這仍是一個持續演進的知識領域,我們目前掌握得並不充分。很明顯地,那些已經出現例如急診就醫(ER visits)等情況的人,相對容易判斷他們因急性臨床後果而處於較高風險。我們也知道在高血糖方面,單就心血管系統而言,長期挑戰就很大——過度的葡萄糖暴露可能是毀滅性的。我不是想迴避問題,只是我不認為現在有人擁有我們正在尋找的那種統計數據。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
Okay and then last question. At this point in time, I don't know if you have this data or not but what percentage of your customers are on insulin pumps?
好的,最後一個問題。就目前而言,我不確定你們是否有這個數據,但你們的客戶中有多少比例在使用胰島素幫浦?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
We don't have that data.
我們沒有那個數據。
Bill Plovanic - Analyst
Bill Plovanic - Analyst
All right. Great. Thanks, Terry. I appreciate it.
好。非常好。謝謝你,Terry。我很感激。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
You bet.
不客氣。
Operator
Operator
We'll go to our next question -- Ben Andrew of William Blair.
我們進入下一個提問——William Blair 的 Ben Andrew。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
Hi. It's actually Matt, in for Ben. There are a couple of quick questions. In terms of conversion from the three to the seven, do you have any sense of the people who have done that so far or how many are expecting to do that over the next couple of months?
嗨。其實我是 Matt,代 Ben 提問。有幾個快速問題。關於從 Three 轉換到 Seven,你們是否掌握目前已經完成轉換的人數,或未來幾個月預計會有多少人轉換?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
We have got a list of patients who have already converted, which we haven't disclosed publicly, and we also have a list of patients that are waiting to receive their upgrade, and again we haven't disclosed that information to the public at this particular point in time.
我們有一份已經完成轉換的病患名單,但我們尚未對外公開;我們也有一份正在等待升級的病患名單,同樣地,目前這個時間點我們也尚未對外披露該資訊。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
Okay. Any sense or attempt to quantify the lost sales in the quarter from the delay in ordering?
好的。那對於因延後下單而導致本季流失的銷售額,你們有沒有任何概念或嘗試量化?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
We haven't quantified that in dollar terms. But again, we think think we experienced about three week delay or hesitation by the customers.
我們沒有以金額來量化。不過,我們認為客戶大約出現了三週的延遲或觀望。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
All right. So we can do the math on that. Last question, sales, any acceleration in turnovers? That has pretty much been tracking as it has been over the last few months.
好,那我們可以自己算。最後一個問題,銷售方面,人員流動是否有加速?基本上看起來跟過去幾個月差不多。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
I haven't -- I have been here five weeks, I haven't seen any sales force change or turn over in that time frame. I think we are pretty stable. I am very comfortable with the current size of the sales force.
我沒有——我來這裡五週了,在這段期間沒有看到銷售團隊有任何變動或流動。我認為我們相當穩定。我對目前銷售團隊的規模很放心。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
No major plans to increase that in the quarter?
本季沒有大幅擴編的計畫?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
No. We are still taking a look at it but our challenge, this is one of the discussions we have had with a number of potential partners about them adding significant sales bodies to carry our product. The problem we're looking at is an to sales force sizing issue, it is getting right to the key thought leaders, getting them to embrace the technology as a primary tool, not a secondary or tertiary tool. That is why we refocused the sales force into these 40 to 50 key clinics at least north of 3,000 type I patients per site in order to get deeper into those particular arenas. I think we're well staffed from that standpoint to simply carry our product isn't somebody else's bag, doesn't make a lot of sense to me right now.
沒有。我們仍在評估,但我們的挑戰——這也是我們與多家潛在合作夥伴討論過的——是他們要增加大量銷售人力來推我們的產品。問題不在於銷售團隊規模怎麼配,而是要接觸到關鍵意見領袖,讓他們把這項技術當作主要工具來採用,而不是第二或第三順位的工具。這也是為什麼我們把銷售團隊重新聚焦在 40 到 50 家關鍵診所上——每個據點至少有 3,000 名第 1 型病患——以便更深入這些場域。我認為就這個角度而言,我們的人力配置已經足夠;單純為了「有人來賣我們的產品」而讓別人來做,現在對我而言並不太合理。
Unidentified Participant - Analyst
Unidentified Participant - Analyst
Okay. Great. Thank you.
好的。非常好。謝謝。
Operator
Operator
We go next to Steve Ogilvie at ThinkEquity.
下一位是 ThinkEquity 的 Steve Ogilvie。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
On the sales force, Terry, how many people do you think you need to adequately cover those 40 to 50 key accounts?
關於銷售團隊,Terry,你認為需要多少人才能充分覆蓋那 40 到 50 個關鍵客戶?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
We are sized at around 45 and I am comfortable with that number, with four regional directors, geographically distributed. On top of that we have five insurance reimbursement specialists. I think that is the right size for the Company right now, and to address adequately the key centers we are approaching, and that we are in.
我們目前規模大約是 45 人,我對這個數字很滿意,並配置四位區域總監、按地理區域分布。此外我們還有五位保險給付專員。我認為以公司目前的狀況來說,這是合適的規模,也足以妥善覆蓋我們正在接觸、以及已經進入的關鍵中心。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
As you said, with the uncertainty of a reimbursement and growth, how do you view the future kind of philosophically, quick revenue ramp? Are you ready to hire a lot more or if it comes for several years, is it something where you send the not or is it 40 to to to 45 people?
如你所說,在給付與成長仍不確定的情況下,你從理念上怎麼看未來?會不會是營收快速爬升?你們是否準備好大幅增聘?或者如果要好幾年才發生,是不是就維持現狀,還是 40 到 45 人?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
That is a big question on your part -- several years, I --- this is trench warfare right now. All of the companies in that space are going to experience the same thing. We did 12 years ago, 10 years ago, when pumps were just being introduced on a more global basis, reimbursement is going to come. It is not a matter of if it is going to come, it is a matter of when it is going to come and we are continuing to see better coverage every month. Again, without broad based coverage, I don't know when that is going to happen.
你的問題很大——好幾年,我——目前這就像壕溝戰。那個領域裡的所有公司都會遇到同樣的情況。就像 12 年前、10 年前,當幫浦開始更全球性地導入時一樣,給付終究會來。不是會不會來的問題,而是什麼時候來的問題,而且我們持續看到每個月都有更好的覆蓋。再說一次,在沒有廣泛覆蓋之前,我不知道那會在什麼時候發生。
If you look at when the JADR of trial are supposedly going to conclude at the end of next year, and so that will be available sometime in the 2009 time frame. When asked about the timing of reimbursement, I have to be vague. I don't know exactly when we're going to get broad-based coverage. I certainly think even today we are getting somewhat off coverage, we see that growing on a monthly basis. But until the time that there is a wide coverage decision by some of the larger third-party payer systems, we're going to keep staff about where we are at in the sales force.
如果你看 JADR 的試驗據稱會在明年年底結束,因此大概在 2009 年的時間點會有結果可用。當被問到給付時程時,我必須說得保守一些。我不確定我們何時能取得廣泛性的覆蓋。我當然認為即使在今天,我們也已經拿到一些覆蓋,而且我們看到它每月都在成長。但在大型第三方支付系統做出更廣泛的覆蓋決策之前,我們會讓銷售團隊的人力大致維持在目前的水準。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
Okay and then last thing, can you just maybe speak to the commercialization of the hospital products, how do you want to push that? Do you think you will leverage your current sales force or is that going to be someone else?
好的,最後一點,你能否談談醫院產品的商業化?你們打算怎麼推?你認為會利用現有銷售團隊,還是會由其他人來做?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
We need to go into partnership clearly with that. We have got a superior technology that is wonderful. We don't understand the hospital market. I know what it takes to build a sales force, I have done it on a couple different occasions, and that is a marketplace that we need to partner up with somebody.
很明顯地,我們需要在這方面尋求合作夥伴。我們有很優越、很棒的技術,但我們不懂醫院市場。我知道建立銷售團隊需要什麼,我也做過幾次;而那是一個我們需要與他人合作的市場。
Operator
Operator
We will go next to Brian Wong, First Albany Capital.
下一位是 First Albany Capital 的 Brian Wong。
Brian Wong - Analyst
Brian Wong - Analyst
Thanks. Good afternoon. Hi. I was wondering if you could talk about the manufacturing process? I believe in the past you said that there were about three areas that you could automate the manufacturing process. One of them was up and running. Are the other two areas now automated or--
謝謝。下午好。嗨。我想請問你能否談談製造流程?我記得你們過去曾說製造流程大概有三個部分可以自動化,其中一個已經上線運作。那另外兩個部分現在也已經自動化了嗎,還是——
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Brian, I am not sure I ever said that. And again, I am looking to the two guys who have been here longer than me for clarification.
Brian,我不確定我是否曾那樣說過。而且,我也想請在我之前就已在這裡的兩位同事幫忙澄清。
Steve Pacelli - SVP, Corporate Affairs
Steve Pacelli - SVP, Corporate Affairs
Yes, Brian. This is Steve. I am not sure we have ever characterize this being three processes that we could automate. I am not sure I follow what you are referring to.
是的,Brian。我是 Steve。我不確定我們是否曾把這件事描述為三個我們可以自動化的流程。我不太確定我理解你指的是什麼。
Brian Wong - Analyst
Brian Wong - Analyst
Okay. I was in my notes from previous -- All right. And in terms of the next generation, I guess the third generation, product, I don't know if I missed this, but did you say the calibration time was going to be different at all from what you have now?
好的。我在我之前的筆記裡——好吧。那麼就下一代,我想是第三代產品而言,我不知道是不是我漏聽了,但你有說校準時間會和你們目前的有任何不同嗎?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
We haven't commented on that. And I am not ready to comment on it on this call.
我們還沒有對此發表評論。而且我也還沒準備好在這通電話上評論。
Brian Wong - Analyst
Brian Wong - Analyst
Then lastly, in terms of your disposables versus the durables sales, would you be able to say whether or not the majority of the revenues came from disposables this quarter or are you still kind of half and half or what?
最後一點,關於你們一次性耗材(disposables)相對於耐用品(durables)的銷售,你們能否說明本季收入是否大多來自耗材?還是仍然大概各半,或是怎麼樣?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
We don't break that out yet. Maybe at some future date, we will, but not for this call, I really don't expect to comment on that when we get into the '08 time frame and I get better optics going forward.
我們目前還沒有把那部分拆分揭露。也許未來某個時間會,但這通電話不會。我也不太預期在進入 2008 年的時間框架、且我對未來有更清楚的能見度之前,會對此做評論。
Brian Wong - Analyst
Brian Wong - Analyst
Got you. All right. That's it for me. Thanks.
了解。好,就這些。謝謝。
Operator
Operator
We'll take our next question from Caroline Corner at Montgomery Company.
我們接下來請 Montgomery Company 的 Caroline Corner 提問。
Caroline Corner - Analyst
Caroline Corner - Analyst
Hi. Thanks for taking my call. So, I just wanted to follow-up a little bit, you said you had some favorable coverage decisions, no broad coverage yet, and that's to be expected at this point. But can you comment on prescription pays vs. purchase pays? I know there has been some commentary around those metrics, I was wondering if you could let us know if prescriptions are still really outpacing purchases? Just if you could comment on that?
嗨,謝謝接聽我的電話。我想再追問一下:你提到你們拿到了一些有利的給付/理賠覆蓋(coverage)決策,但目前還沒有廣泛覆蓋,這在此階段也屬正常。不過你能否評論一下處方給付(prescription pays)相對於購買給付(purchase pays)?我知道外界對這些指標有一些討論,我想了解處方是否仍然大幅領先實際購買?你能否就此評論?
Steve Pacelli - SVP, Corporate Affairs
Steve Pacelli - SVP, Corporate Affairs
Caroline, this is Steve. Let me answer that one. What we disclosed previously is that we received anecdotal evidence from some of the key thought leaders we speak to on a regular basis, they were prescribing the product and those prescriptions were not necessarily translating into orders. Again, we don't have anything we could quantify or disclose at this point. This is just basically reports we are receiving from the field. I haven't seen anything new come in since the last update we were given on that.
Caroline,我是 Steve。我來回答。先前我們揭露的是:我們從一些我們定期交流的關鍵意見領袖那裡收到一些軼聞證據(anecdotal evidence),他們確實在開立該產品的處方,但這些處方不一定轉化為訂單。再次強調,目前我們沒有任何可以量化或揭露的數據。這基本上只是我們從前線收到的回報。自從上次更新之後,我沒有看到任何新的資訊進來。
Caroline Corner - Analyst
Caroline Corner - Analyst
Okay great. That is helpful. The other thing I wanted to ask about with regards to the calibration methods. You said you had a PMA supplement was under review, that means we could use any of the finger stick devices, the blood sugar, but calibration. Could you give us a sense of the timeline when you would be approved? Or other devices?
好的,很好,這很有幫助。另一個我想問的是關於校準方法。你說你們有一個 PMA 補充申請(PMA supplement)正在審查中,這表示我們可以使用任何指尖採血裝置(finger stick devices)來做血糖校準。你能否給我們一個大概的時間表,何時可能獲准?或是其他裝置?
Steve Pacelli - SVP, Corporate Affairs
Steve Pacelli - SVP, Corporate Affairs
Yes. What we said, typically a PMA supplement can take statutorily 180 days, but if the FDA interjects questions, the process can typically take -- We would say between six months plus or minus two. This is not a complicated PMA supplement but I can't guarantee that it will clear, it is within the purview of the FDA at this point. Six to eight months, we could be ready to launch something.
是的。我們的說法是:一般而言,PMA 補充申請在法定上可能需要 180 天,但如果 FDA 插入問題,流程通常會——我們會說大約六個月,正負兩個月。這不是一個複雜的 PMA 補充申請,但我無法保證一定會通過;目前這完全在 FDA 的裁量範圍內。六到八個月,我們可能就能準備好推出某些東西。
Caroline Corner - Analyst
Caroline Corner - Analyst
Final question, with regard to the hospital product, you mentioned partnering -- You said previously that you would be looking for a partner in this area, could you give us more clarity as to when you would get a partner on board? Would it be in the development stage or would it be after you have proof of concept? Where are you thinking of joining with another company in order to get this product out on the market?
最後一個問題,關於醫院用產品。你提到合作——你之前說過你們會在這個領域尋找合作夥伴,你能否更清楚說明何時會讓合作夥伴加入?會是在開發階段,還是在你們有概念驗證(proof of concept)之後?你們打算在什麼階段與另一家公司合作,以便把這個產品推向市場?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
We really haven't discussed that in great detail at the Board level so I will give you my personal opinion as the new CEO and the Board may turn around and smack me for this. My belief system is that we need to take this product well beyond the feasibility and to the pivotal, all the way through a potential PMA filing or whatever the ultimate regulatory pathway is. Obviously during the course of that process to engage in discussions about a distribution partner, but I don't have any intention whatsoever of selling this asset until we have fully recognized and realized the tremendous value this particular product line brings to the Company. So, much later than where we are at today.
我們在董事會層級其實還沒有非常深入地討論,所以我會以新任 CEO 的個人看法來回答——董事會可能會回頭「修理」我。我的信念是:我們需要把這個產品推進到遠超可行性(feasibility)的階段,進入關鍵性試驗(pivotal),一路走到可能的 PMA 申請,或最終的監管路徑。不過在這個過程中,當然會就通路/經銷合作夥伴(distribution partner)展開討論。但在我們充分辨識並實現這條產品線為公司帶來的巨大價值之前,我完全沒有任何意圖出售這項資產。所以會比我們目前所在的階段晚得多。
Caroline Corner - Analyst
Caroline Corner - Analyst
Thanks so much for taking my call and good luck (inaudible).
非常感謝接聽我的電話,祝你好運(聽不清)。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Thanks.
謝謝。
Operator
Operator
We go next to [Alec Barrow, Levart Capital Markets].
接下來我們請 [Alec Barrow, Levart Capital Markets] 提問。
Alec Barrow - Analyst
Alec Barrow - Analyst
Thanks. Good afternoon. Did you give the exact number of days of the 90 in the June quarter that the seven-day (inaudible) was available? I know when it was approved, but when was it actually available to be bought by customers?
謝謝,下午好。你們有沒有提供在 6 月季度 90 天當中,七天(聽不清)實際可供的確切天數?我知道它何時獲准,但它實際上是從什麼時候開始可供客戶購買?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
I'm sorry. You were fading out. Can you repeat the question, please?
抱歉,你的聲音有點斷斷續續。可以請你重複一下問題嗎?
Alec Barrow - Analyst
Alec Barrow - Analyst
I apologize. The questions was, of the 90 days in the quarter, how many the seven-day [essential] was available to be purchased by customers?
不好意思。問題是:在本季 90 天當中,七天 [essential] 有多少天是客戶可以購買的?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
No. We did not. We mentioned the approval date previously of the Seven and there was a hesitation of about three weeks.
沒有。我們先前提過 Seven 的核准日期,而且中間大約延遲了三週。
Steve Pacelli - SVP, Corporate Affairs
Steve Pacelli - SVP, Corporate Affairs
The approval date was May 31st. The ADA was the third week in June. Realistically, in terms of actual days, two to three weeks in the month of June the we had the product technically available.
核准日期是 5 月 31 日。ADA 是 6 月的第三週。就實際天數而言,6 月大概有兩到三週我們在技術上已經讓產品可供使用。
Alec Barrow - Analyst
Alec Barrow - Analyst
Okay. the hesitation, I thought you were describing customers hesitating because they were not available because they were waiting or did you mean was it between when you got the approval and when you made available? Is that what you mean by hesitation?
好的。你說的延遲(hesitation),我原本以為你是在描述客戶因為產品尚未供貨、在等待所以猶豫;還是你指的是從取得核准到你們實際開始供貨之間的延遲?你所說的 hesitation 是這個意思嗎?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Correct. Correct.
對。對。
Alec Barrow - Analyst
Alec Barrow - Analyst
Okay. Was that because you had to ramp up supplies or because you had a specific reason for holding off when it was available?
好的。那是因為你們需要拉升供應量,還是因為有特定原因而延後供貨?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Well, I think we wanted to be sure we had an adequate supply and rollout. Remember, we certainly learned, hopefully from the rampup when we launched the SEF three days, we needed to make sure all systems were in place internally to launch the product.
嗯,我想我們是希望確保有足夠的供應量並做好上市推廣(rollout)。記得,我們當初推出 SEF 三天產品的爬坡(ramp-up)過程中確實學到一些教訓;我們需要確保內部所有系統都已就緒,才能推出產品。
Alec Barrow - Analyst
Alec Barrow - Analyst
My next question is are the product performance issues that came out with a three day sensor in the past, can you say whether the seven day has been free of those? Are there any kind of product performance issues you can comment on?
下一個問題是:過去三天感測器曾出現的產品性能問題,你能否說明七天版本是否已經沒有那些問題?有沒有任何你能評論的產品性能議題?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
I get a weekly complaint data grabbing system from all of the possible complaints and I can tell you they are deminimus in terms compared to the challenges that the three day it -- We're just not getting any of the sensor complaints that we had with the early stage of three day.
我每週都會收到一套彙整所有可能客訴的客訴資料擷取系統報告。我可以告訴你,與三天產品當時的挑戰相比,這些客訴是微不足道(de minimis)的——我們就是沒有收到早期三天產品那種感測器客訴。
Alec Barrow - Analyst
Alec Barrow - Analyst
Okay, my next question is about margins and price points. Is there anything you can give us far as -- as we plot out how the seven day is going to affect your profitability versus what the three day is going to do? Can you give us any direction?
好的。下一個問題是關於毛利與定價。你們能否提供一些資訊——當我們推估七天產品將如何影響你們的獲利能力、相較於三天產品會如何時,你們能給我們任何方向嗎?
Steve Pacelli - SVP, Corporate Affairs
Steve Pacelli - SVP, Corporate Affairs
Not at this point. We're not giving any forward-looking statements with regards to our financial performance at this time.
目前不行。我們此時不會就財務表現提供任何前瞻性陳述。
Alec Barrow - Analyst
Alec Barrow - Analyst
Okay. Even just, how about that there is a higher margin on the seven day than the three day?
好的。那即便只是說,七天的毛利是否高於三天?
Steve Pacelli - SVP, Corporate Affairs
Steve Pacelli - SVP, Corporate Affairs
We're not commenting on that and I would prefer at this point not to speculate or comment. Obviously, in any situation, you have got a bill of materials versus cogs and they are directly affected by quantity. Until we understand our manufacturing process or increase optimization, that number is gong to change literally on a weekly and monthly basis. Right now, we are ramping up from the manufacturing standpoint. Any number I gave you today wouldn't hold within 30 days.
我們不會評論這點,而且我希望此時不要推測或評論。很明顯,在任何情況下,你都有物料清單(bill of materials)相對於銷貨成本(COGS),而且它們會直接受到數量影響。在我們了解製造流程或提升最佳化之前,那個數字會幾乎以每週、每月的頻率變動。現在我們正從製造端進行產能爬坡。我今天給你的任何數字,30 天內都不一定成立。
Alec Barrow - Analyst
Alec Barrow - Analyst
Okay. That is totally understandable. My last question is about the receivers, can you clarify it, is the receiver compatible with the three day sensor or do you need an enhanced receiver to use the seven day?
好的,這完全可以理解。最後一個問題是關於接收器(receiver)。你能否釐清:接收器是否與三天感測器相容?還是需要升級版接收器才能使用七天?
Steve Pacelli - SVP, Corporate Affairs
Steve Pacelli - SVP, Corporate Affairs
Actually, he receiver, we are currently upgrading the receiver. The receiver requires a software upgrade. What we do need to replace with the patients is the transmitter. There is a new [asik] in the transmitter, so we are doing that on a very calculated basis at this point.
其實,接收器我們目前正在升級。接收器需要進行軟體升級。我們需要替病患更換的是發射器(transmitter)。發射器裡有一個新的 [asik],所以我們目前是以非常審慎、可控的方式在進行。
Alec Barrow - Analyst
Alec Barrow - Analyst
Okay. So it is an upgrade? So, patients send in their old receivers, you give them the upgrade and then you send it back to them? Should we be thinking about that when we model it for like a refurbishing program? The trade up of software upgrade?
好的,所以是升級?也就是病患把舊接收器寄回來,你們幫他們升級後再寄回去?我們在建模時是否應該把它視為一個翻新(refurbishing)計畫?也就是軟體升級的換代(trade up)?
Steve Pacelli - SVP, Corporate Affairs
Steve Pacelli - SVP, Corporate Affairs
Yes, I think that is fair. That is how we have (inaudible) the ramp is supposed to occur. We are supplying new patients and working to upgrade those patients that are on the three day that wish to upgrade.
是的,我認為那樣很公平。那就是我們(聽不清)爬坡應該如何發生的方式。我們正在提供新病患,並努力將那些使用三日款且希望升級的病患升級。
Alec Barrow - Analyst
Alec Barrow - Analyst
Okay, and a similar way that you have indicated the top 50 accounts, can you give us a number of how many have been upgraded so far?
好的,類似於你提到的前 50 大帳戶,你能給我們一個數字,說明到目前為止有多少已經升級了嗎?
Steve Pacelli - SVP, Corporate Affairs
Steve Pacelli - SVP, Corporate Affairs
We haven't broken that down.
我們還沒有把那個拆分出來。
Alec Barrow - Analyst
Alec Barrow - Analyst
All right. Thanks very much.
好。非常感謝。
Operator
Operator
We'll take our final question from Sara Michelmore at Cowen and Company.
我們將接聽最後一個問題,來自 Cowen and Company 的 Sara Michelmore。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Hey. Good afternoon. Terry, if I could just ask you to clarify something you said about your source of membrane materials, has that been a key source of variability in the product you look to improve or has it just the membrane you have been receiving hasn't met the specs and hasn't been going into a product?
嗨,下午好。Terry,我想請你澄清一下你提到的膜材料來源:這是否一直是你們想改善的產品中變異性的關鍵來源?還是只是你們收到的膜沒有符合規格,因此沒有被用進產品?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
No. It hasn't been in another product. I mean, we constantly receive materials. We noticed there has been some variability in the materials we have received. So that has required our attention to reduce that variability with the supplier but there is no issue from that standpoint. Obviously my background in operations, I hate single source. I always liked dual -- at least dual source. And so we saw this beginning to show up and having to take in more lots to screen, it became obvious we needed to help the vendor understand what our needs were particularly on a longer-term basis and in the process get a backup supplier ready because this would require regulatory filing. Outside of that I wouldn't read anything into it.
不,沒有用在其他產品上。我的意思是,我們持續在收料。我們注意到收到的材料確實存在一些變異性。因此這需要我們與供應商一起投入注意力來降低變異性,但從那個角度來看沒有問題。顯然以我營運背景來說,我討厭單一來源。我一直偏好雙來源——至少雙來源。所以我們看到這個情況開始出現,而且需要收更多批次來篩選,這就很明顯我們需要協助供應商理解我們的需求,特別是從長期角度;同時也要把備援供應商準備好,因為這會需要進行法規申報。除此之外,我不會對此做過多解讀。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Okay and you mentioned you were heading into a scaling period for the Seven. Obviously when the three day was launched last year the company ran into problems with the scale up. A lot of changes and improvements were made to the manufacturing process at that point. How confident do you feel that the Company is going to be able to pull off a problem-free scale-up process here with the seven day? Is everything in shipshape in terms of the operational piece of it?
好的,你提到你們正進入 Seven 的擴產期。顯然三日款在去年推出時,公司在擴產上遇到問題,當時對製造流程做了很多變更與改善。你對公司這次在七日款上能否順利完成、無問題的擴產流程有多大信心?在營運面上是否一切都已就緒?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
Yes, absolutely. I am looking at yields that come out of the manufacturing environment, and am very happy with the current yield. We are not experiencing any challenges in the seven day. Again, I think we learned from the three day what went right and what went wrong. We corrected what went wrong. No issue to speak of at this point. I think some of our future looking challenges, I would like to see some optimization obviously, from a manufacturing standpoint. We are doing things that I think we can be more efficient at and reduce our CODs but that is the course of the commercialization process the we're not having any difficulty at this point, Sara.
是的,絕對有。我在看製造環境的良率,我對目前的良率非常滿意。我們在七日款上沒有遇到任何挑戰。再說一次,我認為我們從三日款學到了哪些做對、哪些做錯;我們已經修正了做錯的部分。目前沒有任何值得一提的問題。我想未來的一些挑戰是,我希望從製造角度做一些最佳化。我們正在做一些我認為可以更有效率的事情,並降低我們的 CODs(成本)。但這就是商業化過程的一部分;Sara,我們目前沒有任何困難。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Okay. That is great. In terms of calling on the top 30 to 40 partners, I was surprised. Am I correct to interpret that you are at the ground floor with the majority of these accounts just in terms of educating them not only on DexCom, but on the benefit in continuous glucose sensors?
好的,太好了。就拜訪前 30 到 40 個合作夥伴而言,我有點驚訝。我是否可以正確解讀為:就教育這些帳戶而言,你們對其中大多數帳戶仍處於起步階段,不僅是教育他們認識 DexCom,也包括連續血糖感測器的效益?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
I would not say we are at the ground flow. We're beyond that. I mean, you attending the ADA you saw that the two key presentations on Saturday and Sunday morning at 8:00, were all centered on CGM. So, certainly there was a groundswell of information. Where we are is in those key centers, moving this technology from a secondary thought process in the minds of the prescribers, including the educators as well as the prescribing physicians, to more of a primary. Typically, if you think of a sales call our sales people go in, make a call, see the physician and the educators and then walk out. If there are one or two patients that come to mind, that maybe utilization for CGM, they will get put on it. But I want it to be a primary tool when a physician sees a patient or looked at the patient's finger stick records and believes there are elevated HGMC, or their glycemic excursions may be unexplained or just that they are having difficulty maintaining glycemic control, it is primary thought. We are going -- traditionally, you go deep within the organization and also through that process, let them understand how they can utilize this information. Remember: a highly compliant patient may do four to six finger stick measurements a day. We are giving them 288 measurements every 24 hours. That is to help them understand how best to utilize that information.
我不會說我們在起步階段。我們已經超過那個階段了。我的意思是,你參加 ADA 時也看到,週六與週日早上 8:00 的兩場關鍵發表都以 CGM 為核心。所以,資訊的浪潮確實已經形成。我們目前所在的位置是:在那些關鍵中心,將這項技術從處方者(包括衛教師以及開立處方的醫師)心中「次要的思考」轉變為更「主要的思考」。通常你想像一次銷售拜訪,我們的業務人員進去、拜訪、見到醫師與衛教師,然後離開。如果他們想到一兩位可能適合使用 CGM 的病患,就會讓他們使用。但我希望它成為主要工具:當醫師看診,或查看病患的指尖採血紀錄,認為有升高的 HGMC,或血糖波動原因不明,或只是難以維持血糖控制時,CGM 會成為第一時間的想法。我們將——傳統上,你會在組織內深耕,並透過這個過程讓他們了解如何運用這些資訊。請記得:高度配合的病患一天可能做 4 到 6 次指尖採血;我們每 24 小時提供 288 次量測。這是為了幫助他們理解如何最好地運用這些資訊。
What I do find interesting, as you well know, there is a very large diabetes population within the healthcare sector in terms of endocrinologists and diabetes educators who have migrated to that health profession. They are some of our best customers. And they can't live without our product. So obviously they have crossed over that information, to utilize the product effectively and they have become product of champions. But we need that beyond the experts down into the rank-and-file. That is really the goal now , to get it to be more of a primary thought process.
我覺得有趣的是,如你所知,在醫療體系中有非常龐大的糖尿病族群——就內分泌科醫師與糖尿病衛教師而言,有不少人本身就是因為糖尿病而投入這個醫療專業。他們是我們最好的客戶之一,沒有我們的產品就無法生活。所以很顯然,他們已經跨越了那個資訊門檻,能有效使用產品,並成為產品的擁護者。但我們需要把這件事從專家圈擴展到一般基層。這才是現在真正的目標——讓它更成為主要的思考模式。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
If I think about the old model, one of the things you did at that company was scale up support for the customer base in terms of securing reimbursement for the products and also creating training organizations, nurse training organizations to to support the account, can you compare and contrast where you are in the market development and and if you think something larger reimbursement strategy for the Company or training support of force is something we should think about you undertaking over the next three to five years?
如果我回想舊的模式,你在那家公司做的一件事是擴大對客戶群的支援,包括協助產品取得給付,以及建立訓練組織、護理師訓練組織來支援帳戶。你能否比較一下你們目前在市場開發的位置?以及你是否認為,公司在未來三到五年需要採取更大型的給付策略,或建立訓練支援團隊,是我們應該預期你們會著手進行的?
Terry Gregg - President & CEO
Terry Gregg - President & CEO
A couple issues there. Obviously when you have pumps carrying 300 units of a potential lethal drug there was a lot of training issues you had to be particularly cognizant of, and so we spent a lot of the resources to build those up. I don't think sensor technology is as difficult nor as dangerous, quite frankly, as it was in the old pump world. I don't think we need those kind of resources. Certainly, from an education standpoint developing product algorithms in terms of management modules to support physician understanding, patient understanding and payer understanding, these algorithms are things that we currently are engaged in developing. Those types of things, we're going to support, but in terms of the old style, huge customer service insurance reimbursement format don't think we need to develop that from that perspective for CGM.
這裡有幾個議題。顯然,當你有幫浦承載 300 單位、可能致命的藥物時,你必須特別留意大量的訓練議題,因此我們投入了很多資源來建立那些能力。我坦白說,我不認為感測器技術像過去幫浦世界那樣困難或危險。我不覺得我們需要那種規模的資源。當然,從教育角度來看,開發產品演算法(例如管理模組)以支援醫師理解、病患理解以及支付方理解,這些演算法是我們目前正在投入開發的。我們會支援這類事情;但就舊式那種龐大的客服、保險給付處理架構而言,我不認為在 CGM 上需要以那個角度去建立。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
That is helpful, Terry. Thank you so much.
這很有幫助,Terry。非常感謝。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
You bet.
不客氣。
Operator
Operator
I turn things back over to Mr. Gregg for additional closing comments.
我把時間交回給 Gregg 先生,請他做進一步的結語。
Terry Gregg - President & CEO
Terry Gregg - President & CEO
I want to thank everybody for joining us today. OBviously, you see there are a lot of exciting things going on at DexCom as we move Seven forward to the domestic market and into the international market next year. We are well suited to begin to expand the rollout of the product into a larger adoption mentality and also on the horizon, hospital sensor product under development that truly can address a very large unmet medical need in the hospital sector. Thanks for joining us today.
我要感謝大家今天加入我們。很明顯,你們看到 DexCom 正在發生許多令人振奮的事情:我們推進 Seven 進入國內市場,並在明年進入國際市場。我們已具備良好條件,開始擴大產品的推廣,讓採用心態更為普及;同時在不遠的將來,正在開發中的醫院用感測器產品,確實能滿足醫院領域非常龐大的未被滿足醫療需求。感謝大家今天加入我們。
Operator
Operator
Thank you. Once again, everyone, that does include today's teleconference, we appreciate your participation today. You may disconnect at this time.
謝謝。再次感謝各位,今天的電話會議到此結束,我們感謝各位今天的參與。您現在可以掛線。